Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2023

Open Access 01-12-2023 | Fatty Liver | Research

Dietary advanced glycation end products are associated with an increased risk of non-alcoholic fatty liver disease in Iranian adults

Authors: Mitra Kazemi Jahromi, Asal Neshatbini Tehrani, Farshad Teymoori, Ghazal Daftari, Hamid Ahmadirad, Niloufar Saber, Ammar Salehi-Sahlabadi, Hossein Farhadnejad, Parvin Mirmiran

Published in: BMC Endocrine Disorders | Issue 1/2023

Login to get access

Abstract

Background

Dietary advanced glycation end products(AGEs) may contribute to increased inflammation and oxidative stress as risk factors for chronic diseases such as liver disease. In the current study, we aimed to examine the possible association of dietary AGEs with the odds of non-alcoholic fatty liver disease (NAFLD) in Iranian adults.

Methods

A total of 675 participants (225 newly diagnosed NAFLD cases and 450 controls), aged  20–60 years, were recruited for this case-control study. Nutritional data were measured using a validated food frequency questionnaire, and dietary AGEs were determined for all participants. An ultrasound scan of the liver performed the detection of NAFLD in participants of the case group without alcohol consumption and other causes of hepatic disorders. We used logistic regression models, adjusted for potential confounders, to estimate the odds ratios(ORs) and 95% confidence interval(CI) of NAFLD across tertiles of dietary AGEs.

Results

Mean ± SD age and body mass index of the participants were 38.13 ± 8.85 years and 26.85 ± 4.31 kg/m2, respectively. The median(IQR) of dietary AGEs in participants was 3262(2472–4301). In the sex and age-adjusted model, the odds of NAFLD were increased across tertiles of dietary AGEs intake(OR:16.48;95%CI:9.57–28.40, Ptrend<0.001). Also, in the final model, after controlling for confounding effects of BMI, smoking, physical activity, marital status, socio-economic status, and energy intake, the odds of NAFLD were increased across tertiles of dietary AGEs intake(OR:12.16; 95%CI:6.06–24.39, Ptrend<0.001).

Conclusion

Our results showed that greater adherence to dietary pattern with high dietary AGEs intake was significantly related to increased odds of NAFLD.
Literature
1.
go back to reference Sharma M, Mitnala S, Vishnubhotla RK, Mukherjee R, Reddy DN, Rao PN. The riddle of nonalcoholic fatty liver disease: Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis. J Clin Exp Hepatol. 2015;5(2):147–58.PubMedPubMedCentralCrossRef Sharma M, Mitnala S, Vishnubhotla RK, Mukherjee R, Reddy DN, Rao PN. The riddle of nonalcoholic fatty liver disease: Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis. J Clin Exp Hepatol. 2015;5(2):147–58.PubMedPubMedCentralCrossRef
2.
go back to reference Xian Y-X, Weng J-P, Xu F. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chin Med J. 2021;134(01):8–19.CrossRef Xian Y-X, Weng J-P, Xu F. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chin Med J. 2021;134(01):8–19.CrossRef
3.
go back to reference Murag S, Ahmed A, Kim D. Recent epidemiology of nonalcoholic fatty liver disease. Gut Liver. 2021;15(2):206.PubMedCrossRef Murag S, Ahmed A, Kim D. Recent epidemiology of nonalcoholic fatty liver disease. Gut Liver. 2021;15(2):206.PubMedCrossRef
4.
go back to reference Patel R, Baker SS, Liu W, Desai S, Alkhouri R, Kozielski R, et al. Effect of dietary advanced glycation end products on mouse liver. PLoS ONE. 2012;7(4):e35143.PubMedPubMedCentralCrossRef Patel R, Baker SS, Liu W, Desai S, Alkhouri R, Kozielski R, et al. Effect of dietary advanced glycation end products on mouse liver. PLoS ONE. 2012;7(4):e35143.PubMedPubMedCentralCrossRef
5.
go back to reference Dajani A, AbuHammour A. Treatment of nonalcoholic fatty liver disease: where do we stand? An overview. Saudi J gastroenterology: official J Saudi Gastroenterol Association. 2016;22(2):91.CrossRef Dajani A, AbuHammour A. Treatment of nonalcoholic fatty liver disease: where do we stand? An overview. Saudi J gastroenterology: official J Saudi Gastroenterol Association. 2016;22(2):91.CrossRef
6.
go back to reference Fernando DH, Forbes JM, Angus PW, Herath CB. Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products. Int J Mol Sci. 2019;20(20). Fernando DH, Forbes JM, Angus PW, Herath CB. Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products. Int J Mol Sci. 2019;20(20).
7.
go back to reference Fan J-G, Kim S-U, Wong VW-S. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67(4):862–73.PubMedCrossRef Fan J-G, Kim S-U, Wong VW-S. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67(4):862–73.PubMedCrossRef
8.
go back to reference Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):155–61.PubMedCrossRef Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):155–61.PubMedCrossRef
9.
go back to reference Herath HMM, Kodikara I, Weerarathna TP, Liyanage G. Prevalence and associations of non-alcoholic fatty liver disease (NAFLD) in sri lankan patients with type 2 diabetes: a single center study. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2019;13(1):246–50.CrossRef Herath HMM, Kodikara I, Weerarathna TP, Liyanage G. Prevalence and associations of non-alcoholic fatty liver disease (NAFLD) in sri lankan patients with type 2 diabetes: a single center study. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2019;13(1):246–50.CrossRef
10.
go back to reference Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology; 2022. Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology; 2022.
11.
go back to reference Amirkalali B, Poustchi H, Keyvani H, Khansari MR, Ajdarkosh H, Maadi M, et al. Prevalence of non-alcoholic fatty liver disease and its predictors in north of Iran. Iran J public health. 2014;43(9):1275.PubMedPubMedCentral Amirkalali B, Poustchi H, Keyvani H, Khansari MR, Ajdarkosh H, Maadi M, et al. Prevalence of non-alcoholic fatty liver disease and its predictors in north of Iran. Iran J public health. 2014;43(9):1275.PubMedPubMedCentral
12.
go back to reference Zelber-Sagi S, Ratziu V, Oren R. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol. 2011;17(29):3377–89.PubMedPubMedCentralCrossRef Zelber-Sagi S, Ratziu V, Oren R. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol. 2011;17(29):3377–89.PubMedPubMedCentralCrossRef
13.
go back to reference Vanjiappan S, Hamide A, Ananthakrishnan R, Periyasamy SG, Mehalingam V. Nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and its association with cardiovascular disease. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2018;12(4):479–82.CrossRef Vanjiappan S, Hamide A, Ananthakrishnan R, Periyasamy SG, Mehalingam V. Nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and its association with cardiovascular disease. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2018;12(4):479–82.CrossRef
14.
go back to reference Ma J, Hwang S-J, Pedley A, Massaro JM, Hoffmann U, Chung RT, et al. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J Hepatol. 2017;66(2):390–7.PubMedCrossRef Ma J, Hwang S-J, Pedley A, Massaro JM, Hoffmann U, Chung RT, et al. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J Hepatol. 2017;66(2):390–7.PubMedCrossRef
15.
go back to reference Li Y, Wang J, Tang Y, Han X, Liu B, Hu H, et al. Bidirectional association between nonalcoholic fatty liver disease and type 2 diabetes in chinese population: evidence from the Dongfeng-Tongji cohort study. PLoS ONE. 2017;12(3):e0174291.PubMedPubMedCentralCrossRef Li Y, Wang J, Tang Y, Han X, Liu B, Hu H, et al. Bidirectional association between nonalcoholic fatty liver disease and type 2 diabetes in chinese population: evidence from the Dongfeng-Tongji cohort study. PLoS ONE. 2017;12(3):e0174291.PubMedPubMedCentralCrossRef
16.
go back to reference Zelber-Sagi S, Ivancovsky-Wajcman D, Isakov NF, Webb M, Orenstein D, Shibolet O, et al. High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance. J Hepatol. 2018;68(6):1239–46.PubMedCrossRef Zelber-Sagi S, Ivancovsky-Wajcman D, Isakov NF, Webb M, Orenstein D, Shibolet O, et al. High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance. J Hepatol. 2018;68(6):1239–46.PubMedCrossRef
17.
go back to reference Emamat H, Farhadnejad H, Movahedian M, Tangestani H, Mirmiran P, Hekmatdoost A. Dietary sodium intake in relation to non-alcoholic fatty liver disease risk: a case-control study. Nutrition & Food Science; 2020. Emamat H, Farhadnejad H, Movahedian M, Tangestani H, Mirmiran P, Hekmatdoost A. Dietary sodium intake in relation to non-alcoholic fatty liver disease risk: a case-control study. Nutrition & Food Science; 2020.
18.
go back to reference Emamat H, Farhadnejad H, Poustchi H, Hekmatdoost A. Galactose intake is related to nonalcoholic fatty liver disease. Nutrition & Food Science; 2018. Emamat H, Farhadnejad H, Poustchi H, Hekmatdoost A. Galactose intake is related to nonalcoholic fatty liver disease. Nutrition & Food Science; 2018.
19.
go back to reference Clarke RE, Dordevic AL, Tan SM, Ryan L, Coughlan MT. Dietary advanced glycation end products and risk factors for chronic disease: a systematic review of randomised controlled trials. Nutrients. 2016;8(3):125.PubMedPubMedCentralCrossRef Clarke RE, Dordevic AL, Tan SM, Ryan L, Coughlan MT. Dietary advanced glycation end products and risk factors for chronic disease: a systematic review of randomised controlled trials. Nutrients. 2016;8(3):125.PubMedPubMedCentralCrossRef
20.
go back to reference Perrone A, Giovino A, Benny J, Martinelli F. Advanced Glycation End Products (AGEs): Biochemistry, Signaling, Analytical Methods, and Epigenetic Effects. Oxid Med Cell Longev. 2020;2020:3818196.PubMedPubMedCentralCrossRef Perrone A, Giovino A, Benny J, Martinelli F. Advanced Glycation End Products (AGEs): Biochemistry, Signaling, Analytical Methods, and Epigenetic Effects. Oxid Med Cell Longev. 2020;2020:3818196.PubMedPubMedCentralCrossRef
22.
go back to reference Goldberg T, Cai W, Peppa M, Dardaine V, Baliga BS, Uribarri J, et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc. 2004;104(8):1287–91.PubMedCrossRef Goldberg T, Cai W, Peppa M, Dardaine V, Baliga BS, Uribarri J, et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc. 2004;104(8):1287–91.PubMedCrossRef
23.
go back to reference Mirmiran P, Yousefi R, Mottaghi A, Azizi F. Advanced glycation end products and risk of hypertension in iranian adults: Tehran lipid and glucose study. J Res Med sciences: official J Isfahan Univ Med Sci. 2018;23:43.CrossRef Mirmiran P, Yousefi R, Mottaghi A, Azizi F. Advanced glycation end products and risk of hypertension in iranian adults: Tehran lipid and glucose study. J Res Med sciences: official J Isfahan Univ Med Sci. 2018;23:43.CrossRef
24.
go back to reference Mendoza-Herrera K, Aradillas-García C, Mejía-Diaz MA. Association of Dietary Advanced Glycation End Products with Metabolic Syndrome in Young Mexican Adults. 2018;5(4). Mendoza-Herrera K, Aradillas-García C, Mejía-Diaz MA. Association of Dietary Advanced Glycation End Products with Metabolic Syndrome in Young Mexican Adults. 2018;5(4).
25.
go back to reference Rungratanawanich W, Qu Y, Wang X, Essa MM, Song BJ. Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury. Exp Mol Med. 2021;53(2):168–88.PubMedPubMedCentralCrossRef Rungratanawanich W, Qu Y, Wang X, Essa MM, Song BJ. Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury. Exp Mol Med. 2021;53(2):168–88.PubMedPubMedCentralCrossRef
26.
go back to reference Sakasai-Sakai A, Takata T, Takino J-i, Takeuchi M. Impact of intracellular glyceraldehyde-derived advanced glycation end-products on human hepatocyte cell death. Sci Rep. 2017;7(1):1–11.CrossRef Sakasai-Sakai A, Takata T, Takino J-i, Takeuchi M. Impact of intracellular glyceraldehyde-derived advanced glycation end-products on human hepatocyte cell death. Sci Rep. 2017;7(1):1–11.CrossRef
27.
go back to reference Gaens KH, Niessen PM, Rensen SS, Buurman WA, Greve JWM, Driessen A, et al. Endogenous formation of Nε-(carboxymethyl) lysine is increased in fatty livers and induces inflammatory markers in an in vitro model of hepatic steatosis. J Hepatol. 2012;56(3):647–55.PubMedCrossRef Gaens KH, Niessen PM, Rensen SS, Buurman WA, Greve JWM, Driessen A, et al. Endogenous formation of Nε-(carboxymethyl) lysine is increased in fatty livers and induces inflammatory markers in an in vitro model of hepatic steatosis. J Hepatol. 2012;56(3):647–55.PubMedCrossRef
28.
go back to reference Esmaillzadeh A, Kimiagar M, Mehrabi Y, Azadbakht L, Hu FB, Willett WC. Dietary patterns, insulin resistance, and prevalence of the metabolic syndrome in women. Am J Clin Nutr. 2007;85(3):910–8.PubMedCrossRef Esmaillzadeh A, Kimiagar M, Mehrabi Y, Azadbakht L, Hu FB, Willett WC. Dietary patterns, insulin resistance, and prevalence of the metabolic syndrome in women. Am J Clin Nutr. 2007;85(3):910–8.PubMedCrossRef
29.
go back to reference Ghaffarpour M, Houshiar-Rad A, Kianfar H. The manual for household measures, cooking yields factors and edible portion of foods. Tehran: Nashre Olume Keshavarzy. 1999;7(213):42–58. Ghaffarpour M, Houshiar-Rad A, Kianfar H. The manual for household measures, cooking yields factors and edible portion of foods. Tehran: Nashre Olume Keshavarzy. 1999;7(213):42–58.
30.
go back to reference Bowman SA, Friday JE, Moshfegh AJ. MyPyramid equivalents database, 2.0 for USDA survey foods, 2003–2004: documentation and user guide. US Department of Agriculture; 2008. Bowman SA, Friday JE, Moshfegh AJ. MyPyramid equivalents database, 2.0 for USDA survey foods, 2003–2004: documentation and user guide. US Department of Agriculture; 2008.
31.
go back to reference Azar M. In: Sarkisian E, editor. Food composition table of Iran. Volume 65. Tehran: National Nutrition and Food Research Institute, Shaheed Beheshti University; 1980. Azar M. In: Sarkisian E, editor. Food composition table of Iran. Volume 65. Tehran: National Nutrition and Food Research Institute, Shaheed Beheshti University; 1980.
32.
go back to reference Uribarri J, Woodruff S, Goodman S, Cai W, Chen X, Pyzik R, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc. 2010;110(6):911–16e12.PubMedPubMedCentralCrossRef Uribarri J, Woodruff S, Goodman S, Cai W, Chen X, Pyzik R, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc. 2010;110(6):911–16e12.PubMedPubMedCentralCrossRef
33.
go back to reference Moghaddam MB, Aghdam FB, Jafarabadi MA, Allahverdipour H, Nikookheslat SD, Safarpour S. The iranian version of International Physical Activity Questionnaire (IPAQ) in Iran: content and construct validity, factor structure, internal consistency and stability. World Appl Sci J. 2012;18(8):1073–80. Moghaddam MB, Aghdam FB, Jafarabadi MA, Allahverdipour H, Nikookheslat SD, Safarpour S. The iranian version of International Physical Activity Questionnaire (IPAQ) in Iran: content and construct validity, factor structure, internal consistency and stability. World Appl Sci J. 2012;18(8):1073–80.
34.
go back to reference Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, et al. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc. 2000;32(9):S498–S504.PubMedCrossRef Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, et al. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc. 2000;32(9):S498–S504.PubMedCrossRef
35.
go back to reference Lee PH, Macfarlane DJ, Lam TH, Stewart SM. Validity of the international physical activity questionnaire short form (IPAQ-SF): a systematic review. Int J Behav Nutr Phys activity. 2011;8(1):1–11.CrossRef Lee PH, Macfarlane DJ, Lam TH, Stewart SM. Validity of the international physical activity questionnaire short form (IPAQ-SF): a systematic review. Int J Behav Nutr Phys activity. 2011;8(1):1–11.CrossRef
36.
go back to reference Garmaroudi GR, Moradi A. Socio-economic status in Iran: a study of measurement index. Payesh (Health Monitor). 2010;9(2):137–44. Garmaroudi GR, Moradi A. Socio-economic status in Iran: a study of measurement index. Payesh (Health Monitor). 2010;9(2):137–44.
37.
go back to reference Mirmiran P, Esfandiari S, Bahadoran Z, Tohidi M, Azizi F. Dietary insulin load and insulin index are associated with the risk of insulin resistance: a prospective approach in tehran lipid and glucose study. J Diabetes Metabolic Disorders. 2015;15(1):1–7.CrossRef Mirmiran P, Esfandiari S, Bahadoran Z, Tohidi M, Azizi F. Dietary insulin load and insulin index are associated with the risk of insulin resistance: a prospective approach in tehran lipid and glucose study. J Diabetes Metabolic Disorders. 2015;15(1):1–7.CrossRef
38.
go back to reference Mirmiran P, Teymoori F, Farhadnejad H, Mokhtari E, Salehi-Sahlabadi A. Nitrate containing vegetables and dietary nitrate and nonalcoholic fatty liver disease: a case control study. Nutr J. 2023;22(1):3.PubMedPubMedCentralCrossRef Mirmiran P, Teymoori F, Farhadnejad H, Mokhtari E, Salehi-Sahlabadi A. Nitrate containing vegetables and dietary nitrate and nonalcoholic fatty liver disease: a case control study. Nutr J. 2023;22(1):3.PubMedPubMedCentralCrossRef
39.
go back to reference Wada K, Nakashima Y, Yamakawa M, Hori A, Seishima M, Tanabashi S, et al. Dietary advanced glycation end products and cancer risk in Japan: from the Takayama study. Cancer Sci. 2022;113(8):2839–48.PubMedPubMedCentralCrossRef Wada K, Nakashima Y, Yamakawa M, Hori A, Seishima M, Tanabashi S, et al. Dietary advanced glycation end products and cancer risk in Japan: from the Takayama study. Cancer Sci. 2022;113(8):2839–48.PubMedPubMedCentralCrossRef
40.
go back to reference Goodwin M, Herath C, Jia Z, Leung C, Coughlan MT, Forbes J, et al. Advanced glycation end products augment experimental hepatic fibrosis. J Gastroenterol Hepatol. 2013;28(2):369–76.PubMedCrossRef Goodwin M, Herath C, Jia Z, Leung C, Coughlan MT, Forbes J, et al. Advanced glycation end products augment experimental hepatic fibrosis. J Gastroenterol Hepatol. 2013;28(2):369–76.PubMedCrossRef
41.
go back to reference Leung C, Herath CB, Jia Z, Goodwin M, Mak KY, Watt MJ, et al. Dietary glycotoxins exacerbate progression of experimental fatty liver disease. J Hepatol. 2014;60(4):832–8.PubMedCrossRef Leung C, Herath CB, Jia Z, Goodwin M, Mak KY, Watt MJ, et al. Dietary glycotoxins exacerbate progression of experimental fatty liver disease. J Hepatol. 2014;60(4):832–8.PubMedCrossRef
42.
go back to reference Leung C, Herath CB, Jia Z, Andrikopoulos S, Brown BE, Davies MJ, et al. Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease. World J Gastroenterol. 2016;22(35):8026–40.PubMedPubMedCentralCrossRef Leung C, Herath CB, Jia Z, Andrikopoulos S, Brown BE, Davies MJ, et al. Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease. World J Gastroenterol. 2016;22(35):8026–40.PubMedPubMedCentralCrossRef
43.
go back to reference Hyogo H, Ikegami T, Tokushige K, Hashimoto E, Inui K, Matsuzaki Y, et al. Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study. Hepatol Res. 2011;41(11):1057–65.PubMedCrossRef Hyogo H, Ikegami T, Tokushige K, Hashimoto E, Inui K, Matsuzaki Y, et al. Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study. Hepatol Res. 2011;41(11):1057–65.PubMedCrossRef
44.
go back to reference Pereira E, Paula DP, de Araujo BP, da Fonseca MJM, Diniz M, Daliry A, et al. Advanced glycation end product: a potential biomarker for risk stratification of non-alcoholic fatty liver disease in ELSA-Brasil study. World J Gastroenterol. 2021;27(29):4913–28.PubMedPubMedCentralCrossRef Pereira E, Paula DP, de Araujo BP, da Fonseca MJM, Diniz M, Daliry A, et al. Advanced glycation end product: a potential biomarker for risk stratification of non-alcoholic fatty liver disease in ELSA-Brasil study. World J Gastroenterol. 2021;27(29):4913–28.PubMedPubMedCentralCrossRef
45.
go back to reference Palma-Duran SA, Kontogianni MD, Vlassopoulos A, Zhao S, Margariti A, Georgoulis M, et al. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults. Metabolism. 2018;83:120–7.PubMedCrossRef Palma-Duran SA, Kontogianni MD, Vlassopoulos A, Zhao S, Margariti A, Georgoulis M, et al. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults. Metabolism. 2018;83:120–7.PubMedCrossRef
46.
go back to reference Priken K, Tapia G, Cadagan C, Quezada N, Torres J, D’Espessailles A, et al. Higher hepatic advanced glycation end products and liver damage markers are associated with nonalcoholic steatohepatitis. Nutr Res. 2022;104:71–81.PubMedCrossRef Priken K, Tapia G, Cadagan C, Quezada N, Torres J, D’Espessailles A, et al. Higher hepatic advanced glycation end products and liver damage markers are associated with nonalcoholic steatohepatitis. Nutr Res. 2022;104:71–81.PubMedCrossRef
47.
go back to reference Huang JS, Guh JY, Chen HC, Hung WC, Lai YH, Chuang LY. Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J Cell Biochem. 2001;81(1):102–13.PubMedCrossRef Huang JS, Guh JY, Chen HC, Hung WC, Lai YH, Chuang LY. Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J Cell Biochem. 2001;81(1):102–13.PubMedCrossRef
48.
go back to reference Iwamoto K, Kanno K, Hyogo H, Yamagishi S, Takeuchi M, Tazuma S, et al. Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells. J Gastroenterol. 2008;43(4):298–304.PubMedCrossRef Iwamoto K, Kanno K, Hyogo H, Yamagishi S, Takeuchi M, Tazuma S, et al. Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells. J Gastroenterol. 2008;43(4):298–304.PubMedCrossRef
49.
go back to reference Zhan SS, Jiang JX, Wu J, Halsted C, Friedman SL, Zern MA, et al. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology. 2006;43(3):435–43.PubMedCrossRef Zhan SS, Jiang JX, Wu J, Halsted C, Friedman SL, Zern MA, et al. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology. 2006;43(3):435–43.PubMedCrossRef
50.
go back to reference Miyata T, Hori O, Zhang J, Yan SD, Ferran L, Iida Y, et al. The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. J Clin Invest. 1996;98(5):1088–94.PubMedPubMedCentralCrossRef Miyata T, Hori O, Zhang J, Yan SD, Ferran L, Iida Y, et al. The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. J Clin Invest. 1996;98(5):1088–94.PubMedPubMedCentralCrossRef
51.
go back to reference Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med. 2008;14(2):72–81.PubMedCrossRef Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med. 2008;14(2):72–81.PubMedCrossRef
52.
go back to reference Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007;45(6):1366–74.PubMedCrossRef Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007;45(6):1366–74.PubMedCrossRef
53.
go back to reference Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med. 2002;251(2):87–101.PubMedCrossRef Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med. 2002;251(2):87–101.PubMedCrossRef
54.
go back to reference Baynes JW. The Maillard hypothesis on aging: time to focus on DNA. Ann N Y Acad Sci. 2002;959:360–7.PubMedCrossRef Baynes JW. The Maillard hypothesis on aging: time to focus on DNA. Ann N Y Acad Sci. 2002;959:360–7.PubMedCrossRef
Metadata
Title
Dietary advanced glycation end products are associated with an increased risk of non-alcoholic fatty liver disease in Iranian adults
Authors
Mitra Kazemi Jahromi
Asal Neshatbini Tehrani
Farshad Teymoori
Ghazal Daftari
Hamid Ahmadirad
Niloufar Saber
Ammar Salehi-Sahlabadi
Hossein Farhadnejad
Parvin Mirmiran
Publication date
01-12-2023
Publisher
BioMed Central
Keyword
Fatty Liver
Published in
BMC Endocrine Disorders / Issue 1/2023
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-023-01365-8

Other articles of this Issue 1/2023

BMC Endocrine Disorders 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine